Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis and Metrics

Mirum Pharmaceuticals

NASDAQ: MIRM

$113.05 ▼ -1.31 (-1.15%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap6.66 Bn

P/E-8.34

P/S11.69

Div. Yield0.00

Revenue Growth (1y) (Qtr)43.28

Add ratio to table…

About

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases. The company commercializes three approved medicines: Livmarli for cholestatic pruritus in Alagille syndrome and progressive familial intrahepatic cholestasis, Cholbam for bile acid synthesis disorders and peroxisomal disorders, and Ctexli for cerebrotendinous xanthomatosis. In addition, Mirum advances a pipeline of product candidates including volixibat for primary sclerosing cholangitis and primary biliary cholangitis, brelovitug for chronic hepatitis D virus infection, and MRM-3379 for fragile X syndrome. The firm focuses its efforts on orphan indications where unmet medical need is high.

Mirum generates revenue primarily from the sale of its approved medicines Livmarli, Cholbam, and Ctexli in the United States, Canada, and select European countries through a specialized commercial team. The company also earns revenue from licensing and distribution agreements with rare disease partners that enable commercialization of its products in additional territories. Furthermore, milestone payments and royalties from collaborative agreements contribute to its overall income.

Within the rare disease biopharmaceutical sector, Mirum holds a competitive position through its approved therapies for niche liver conditions and its pipeline targeting underserved indications. Key competitors include GlaxoSmithKline and Ipsen which develop IBAT inhibitors for similar cholestatic diseases, as well as companies pursuing gene therapy solutions for progressive familial intrahepatic cholestasis. For its hepatitis D candidate, Mirum faces competition from Gilead Sciences’ bulevirtide and other investigational agents. In the fragile X syndrome space, rivals such as Shionogi and Harmony Biosciences are advancing PDE4D inhibitors. Mirum’s advantages stem from its orphan drug exclusivities, specialized sales force focused on rare disease specialists, and a broad intellectual property portfolio that protects its product candidates.

The company serves patients with rare liver and genetic diseases, their treating physicians, and specialized healthcare providers. Its products are distributed through specialty pharmacies, third party logistics providers, authorized distributors, and licensed partners in various jurisdictions. In certain markets, government agencies also place periodic orders for its medicines.

Investment Thesis

▲ Bull case

Mirum Pharmaceuticals is positioned for significant revenue growth driven by the accelerating adoption of LIVMARLI in the U.S. PFIC market, particularly among adult patients, which management identified as the primary driver of its Q1 sales increase and the basis for raising full-year 2026 net product sales guidance to $660 million to $680 million. This guidance increase reflects stronger-than-expected performance in both U.S. and international markets, with PFIC demand exceeding initial forecasts due to successful education efforts targeting adult liver providers who are increasingly recognizing and treating genetic cholestasis in older patient populations. The company’s commercial execution is further bolstered by its planned expansion of the U.S. liver field team from 20 to approximately 60 personnel by early next year, which will enable coverage of over 4,000 liver health care professionals across pediatric and adult specialties—representing the vast majority of potential prescribers. This expansion directly addresses a key unmet need in diagnosing and treating adult PFIC patients, a demographic historically underserved due to limited provider awareness, and creates a scalable pathway to capture additional market share as the EXPAND indication for LIVMARLI progresses, which management reiterated represents about one-third of at least a $1 billion peak sales opportunity for the drug. The combination of expanding commercial reach, growing demand in adult PFIC, and the upcoming EXPAND data readout later this year positions LIVMARLI for sustained multi-year growth beyond its current pediatric foundation.
The clinical progress in Mirum’s rare liver disease pipeline presents substantial near-term catalysts that the market may be underestimating, particularly the potential for volixibat to become the first approved therapy in the U.S. for primary sclerosing cholangitis (PSC) and berlivatig for hepatitis delta virus (HDV). The VISTAS study of volixibat in PSC demonstrated statistically significant and clinically meaningful reductions in pruritus, meeting its primary endpoint and supporting a planned NDA submission in the second half of 2026, with a pre-NDA meeting scheduled with the FDA in summer 2026. Similarly, the AZURE-1 Phase 2b study of berlivatig in HDV achieved the primary composite endpoint of virologic response and ALT normalization at Week 24 in both dose arms, reinforcing its potential in a patient population with extremely limited treatment options. Both volixibat and berlivatig have received FDA Breakthrough Therapy designation, which could accelerate review timelines and increase the likelihood of approval. Management emphasized that these programs build directly on Mirum’s existing commercialization platform for LIVMARLI, leveraging shared infrastructure, technologies, and field teams, which reduces incremental launch costs and accelerates time-to-revenue. The upcoming late-breaking presentations at EASL 2026 and the anticipated NDA submissions for both assets later in 2026 represent tangible, value-creating milestones that could significantly expand Mirum’s addressable market beyond its current rare pediatric liver disease focus into larger adult populations with significant unmet need.
The acquisition of worldwide rights to zolergosertib for fibrodysplasia ossificans progressiva (FOP) represents a transformative addition to Mirum’s rare genetic disease platform, with strong potential for rapid revenue contribution and peak sales exceeding $200 million globally. The NDA for zolergosertib was accepted with priority review and a PDUFA date set for September 26, 2026, with an anticipated U.S. launch by year-end if approved. Mirum highlighted that it has full access to clinical data, regulatory correspondence, and the NDA from Incyte, providing strong confidence in the asset’s profile and regulatory progress—a detail underscored by CEO Peetz during the Q&A when addressing concerns about limited public data. The PROGRESS study, which formed the basis of the NDA, is expected to be presented at ENDO 2026 in June 2026, offering early visibility into pivotal efficacy and safety results before the PDUFA date. Zolergosertib’s once-daily oral administration represents a meaningful differentiation from existing therapies like Sohonos (palovarotene), which are associated with tolerability and safety challenges, and garetosmab, which requires intravenous infusion. Management noted that the oral route is a significant advantage in a patient population where minimizing treatment burden is critical, and they plan to leverage their existing rare genetics team—already engaged with specialized centers that prescribe CTEXLI and CHOLBAM—to efficiently commercialize the product. With approximately 300 identified FOP patients in the U.S. (age 12+ at launch per the NDA scope) and a mid- to high-single-digit royalty structure where Incyte retains any rare pediatric disease priority review voucher, Mirum retains substantial upside from sales-based milestones and royalties. The product is expected to be accretive very quickly post-launch, and its integration into Mirum’s established rare genetic disease commercial infrastructure minimizes launch risk while maximizing speed to market.
Despite the significant one-time expenses from the Bluejay Therapeutics acquisition impacting Q1 operating expenses, Mirum maintains a robust financial foundation that supports continued investment without compromising long-term strength, with cash, cash equivalents, and investments growing to $421 million as of March 31, 2026—up from $391 million at the start of the year. The company generated approximately $2 million in cash flow from operations during the quarter, and management reiterated its expectation to achieve operating cash flow positivity in 2027, with GAAP profitability targeted for 2028. Importantly, the CFO clarified that the $949 million in total operating expenses included $761 million tied to the Bluejay acquisition, which he characterized as one-time and nonrecurring, distinguishing it from the underlying operating cost structure. R&D and SG&A expenses were $98 million and $96 million respectively, reflecting ongoing investment in pipeline programs like berlivatig and zolergosertib, which are fully funded. The company also received $260 million in net financing proceeds that offset the $253 million net cash out for the Bluejay acquisition, leaving cash reserves intact. This financial discipline, combined with a growing commercial base and mid-50% range cash contribution margin at the product level, provides ample runway to support pre-launch investments in berlivatig and zolergosertib while advancing toward profitability. The ability to grow cash reserves post-acquisition underscores the resilience of Mirum’s core business and its capacity to fund growth internally, reducing reliance on external dilution and reinforcing investor confidence in its long-term value creation potential.

Mirum Pharmaceuticals is positioned for significant revenue growth driven by the accelerating adoption of LIVMARLI in the U.S. PFIC market, particularly among adult patients, which management identified as the primary driver of its Q1 sales increase and the basis for raising full-year 2026 net product sales guidance to $660 million to $680 million. This guidance increase reflects stronger-than-expected performance in both U.S. and international markets, with PFIC demand exceeding initial forecasts due to successful education efforts targeting adult liver providers who are increasingly recognizing and treating genetic cholestasis in older patient populations. The company’s commercial execution is further bolstered by its planned expansion of the U.S. liver field team from 20 to approximately 60 personnel by early next year, which will enable coverage of over 4,000 liver health care professionals across pediatric and adult specialties—representing the vast majority of potential prescribers. This expansion directly addresses a key unmet need in diagnosing and treating adult PFIC patients, a demographic historically underserved due to limited provider awareness, and creates a scalable pathway to capture additional market share as the EXPAND indication for LIVMARLI progresses, which management reiterated represents about one-third of at least a $1 billion peak sales opportunity for the drug. The combination of expanding commercial reach, growing demand in adult PFIC, and the upcoming EXPAND data readout later this year positions LIVMARLI for sustained multi-year growth beyond its current pediatric foundation.
The clinical progress in Mirum’s rare liver disease pipeline presents substantial near-term catalysts that the market may be underestimating, particularly the potential for volixibat to become the first approved therapy in the U.S. for primary sclerosing cholangitis (PSC) and berlivatig for hepatitis delta virus (HDV). The VISTAS study of volixibat in PSC demonstrated statistically significant and clinically meaningful reductions in pruritus, meeting its primary endpoint and supporting a planned NDA submission in the second half of 2026, with a pre-NDA meeting scheduled with the FDA in summer 2026. Similarly, the AZURE-1 Phase 2b study of berlivatig in HDV achieved the primary composite endpoint of virologic response and ALT normalization at Week 24 in both dose arms, reinforcing its potential in a patient population with extremely limited treatment options. Both volixibat and berlivatig have received FDA Breakthrough Therapy designation, which could accelerate review timelines and increase the likelihood of approval. Management emphasized that these programs build directly on Mirum’s existing commercialization platform for LIVMARLI, leveraging shared infrastructure, technologies, and field teams, which reduces incremental launch costs and accelerates time-to-revenue. The upcoming late-breaking presentations at EASL 2026 and the anticipated NDA submissions for both assets later in 2026 represent tangible, value-creating milestones that could significantly expand Mirum’s addressable market beyond its current rare pediatric liver disease focus into larger adult populations with significant unmet need.
The acquisition of worldwide rights to zolergosertib for fibrodysplasia ossificans progressiva (FOP) represents a transformative addition to Mirum’s rare genetic disease platform, with strong potential for rapid revenue contribution and peak sales exceeding $200 million globally. The NDA for zolergosertib was accepted with priority review and a PDUFA date set for September 26, 2026, with an anticipated U.S. launch by year-end if approved. Mirum highlighted that it has full access to clinical data, regulatory correspondence, and the NDA from Incyte, providing strong confidence in the asset’s profile and regulatory progress—a detail underscored by CEO Peetz during the Q&A when addressing concerns about limited public data. The PROGRESS study, which formed the basis of the NDA, is expected to be presented at ENDO 2026 in June 2026, offering early visibility into pivotal efficacy and safety results before the PDUFA date. Zolergosertib’s once-daily oral administration represents a meaningful differentiation from existing therapies like Sohonos (palovarotene), which are associated with tolerability and safety challenges, and garetosmab, which requires intravenous infusion. Management noted that the oral route is a significant advantage in a patient population where minimizing treatment burden is critical, and they plan to leverage their existing rare genetics team—already engaged with specialized centers that prescribe CTEXLI and CHOLBAM—to efficiently commercialize the product. With approximately 300 identified FOP patients in the U.S. (age 12+ at launch per the NDA scope) and a mid- to high-single-digit royalty structure where Incyte retains any rare pediatric disease priority review voucher, Mirum retains substantial upside from sales-based milestones and royalties. The product is expected to be accretive very quickly post-launch, and its integration into Mirum’s established rare genetic disease commercial infrastructure minimizes launch risk while maximizing speed to market.
Despite the significant one-time expenses from the Bluejay Therapeutics acquisition impacting Q1 operating expenses, Mirum maintains a robust financial foundation that supports continued investment without compromising long-term strength, with cash, cash equivalents, and investments growing to $421 million as of March 31, 2026—up from $391 million at the start of the year. The company generated approximately $2 million in cash flow from operations during the quarter, and management reiterated its expectation to achieve operating cash flow positivity in 2027, with GAAP profitability targeted for 2028. Importantly, the CFO clarified that the $949 million in total operating expenses included $761 million tied to the Bluejay acquisition, which he characterized as one-time and nonrecurring, distinguishing it from the underlying operating cost structure. R&D and SG&A expenses were $98 million and $96 million respectively, reflecting ongoing investment in pipeline programs like berlivatig and zolergosertib, which are fully funded. The company also received $260 million in net financing proceeds that offset the $253 million net cash out for the Bluejay acquisition, leaving cash reserves intact. This financial discipline, combined with a growing commercial base and mid-50% range cash contribution margin at the product level, provides ample runway to support pre-launch investments in berlivatig and zolergosertib while advancing toward profitability. The ability to grow cash reserves post-acquisition underscores the resilience of Mirum’s core business and its capacity to fund growth internally, reducing reliance on external dilution and reinforcing investor confidence in its long-term value creation potential.

▼ Bear case

Mirum Pharmaceuticals faces significant near-term profitability headwinds due to escalating R&D investments required to support the imminent launches of berlivatig for HDV and zolergosertib for FOP, which management acknowledged will delay GAAP profitability until 2028 despite targeting operating cash flow positivity in 2027. The CFO explicitly stated that R&D expense will step up in 2026 as pre-launch investments in berlivatig increase ahead of its anticipated BLA submission next year, noting that the first quarter already included $21 million related to berlivatig’s development. This increase is expected to be fully funded, but it represents a material and sustained uplift in operating expenses that will compress margins and extend the timeline to profitability. While management emphasized financial independence, the sheer scale of these investments—combined with ongoing costs for the sales force expansion and potential commercialization activities for volixibat—creates a scenario where profitability remains elusive for multiple years, even if revenue guidance is met. The market may be underestimating the duration and intensity of this investment phase, particularly given that the company is simultaneously advancing three late-stage pipeline assets (volixibat, berlivatig, zolergosertib) toward potential approval and launch, each requiring substantial pre-launch spending on manufacturing, medical affairs, and market access. This prolonged investment window increases execution risk and could lead to investor impatience if clinical or regulatory milestones slip, especially given the company’s history of operating losses and the high valuation implied by its current growth expectations.
The commercial opportunity for LIVMARLI’s EXPAND indication, while cited by management as representing about one-third of at least a $1 billion peak sales opportunity, remains unproven and contingent on positive results from the ongoing Phase 3 EXPAND study, which has not yet read out. Management’s characterization of this opportunity as a near-term catalyst may be overly optimistic, as the study is evaluating additional settings of cholestatic pruritus beyond PFIC and Alagille, including intrahepatic cholestasis of pregnancy (ICP), and there is no guarantee of regulatory approval or reimbursement support in these broader indications. The company has not disclosed specific timelines for EXPAND readout or NDA submission, and the reliance on this indication to drive significant long-term growth introduces uncertainty, especially if the data fail to demonstrate a clinically meaningful benefit or if payer resistance emerges in newer, less established patient populations. Furthermore, LIVMARLI’s current label carries important limitations, including a boxed warning for liver injury and restrictions in PFIC type 2 patients with severe BSEP defects, which could complicate expansion into broader cholestatic populations where underlying liver heterogeneity is higher. The market may be assigning excessive value to the EXPAND opportunity without sufficient visibility into the study’s progress or the commercial viability of launching into indications where Mirum lacks established physician relationships or real-world evidence.
The FOP market for zolergosertib is inherently constrained by the disease’s ultra-rare prevalence, with only approximately 300 identified patients in the U.S. and 900 globally, which imposes a hard ceiling on revenue potential regardless of pricing or penetration. Management’s peak sales guidance of $200 million plus globally implies an exceptionally high annual revenue per patient—exceeding $600,000 per patient per year in the U.S. alone if fully penetrated—which raises questions about pricing sustainability and payer receptiveness, particularly in a landscape where ultra-rare disease therapies face increasing scrutiny from insurers and pharmacy benefit managers over cost-effectiveness. While the company compared pricing to Niemann-Pick C products, those analogs may not fully capture the unique burden of FOP, where patients often require multidisciplinary care and face significant disability, potentially limiting willingness to pay at such elevated levels. Additionally, the NDA is limited to patients age 12 and over, excluding a meaningful portion of the FOP population diagnosed in early childhood, and while management noted ongoing cohorts for younger ages, there is no guarantee of label expansion or timely data readouts to support it. The reliance on Incyte to complete the primary role through approval, with Mirum assuming sponsorship only post-approval, introduces operational handoff risk, and the fact that Incyte retains any rare pediatric disease priority review voucher—should one be awarded—reduces Mirum’s potential upside from non-economic incentives. The market may be overlooking these structural constraints and overestimating the speed and depth of penetration in a niche, challenging-to-reach patient population where diagnosis remains difficult and treatment paradigms are entrenched.
Mirum’s growing dependence on external partnerships and licensing deals—exemplified by the zolergosertib agreement with Incyte and the historical in-licensing of assets like CHOLBAM and CTEXLI—creates vulnerability to counterparty actions and reduces control over key pipeline assets, particularly regarding regulatory strategy, timing, and economic terms. In the zolergosertib deal, Incyte retains the rare pediatric disease priority review voucher if awarded, controls the primary regulatory role through approval, and is eligible for sales-based milestones and royalties, which means Mirum’s upside is capped and its downstream success is tied to Incyte’s execution. While management expressed confidence in the asset based on full access to data and regulatory correspondence, the company does not own the underlying intellectual property or development program outright, limiting its ability to influence critical decisions. This pattern extends to other pipeline assets: volixibat and berlivatig are internally developed, but the company’s reliance on external innovation for key growth drivers like zolergosertib introduces strategic fragility. If Incyte prioritizes other programs or encounters delays in the PROGRESS study readout or FDA review, Mirum’s timeline for launch and revenue recognition could slip, directly impacting its 2026 revenue guidance and long-term valuation. The market may be assuming seamless execution of these partnerships without adequately weighing the risks of misaligned incentives, clinical setbacks at the partner level, or changes in partner strategy that could diminish Mirum’s expected benefits.

Mirum Pharmaceuticals faces significant near-term profitability headwinds due to escalating R&D investments required to support the imminent launches of berlivatig for HDV and zolergosertib for FOP, which management acknowledged will delay GAAP profitability until 2028 despite targeting operating cash flow positivity in 2027. The CFO explicitly stated that R&D expense will step up in 2026 as pre-launch investments in berlivatig increase ahead of its anticipated BLA submission next year, noting that the first quarter already included $21 million related to berlivatig’s development. This increase is expected to be fully funded, but it represents a material and sustained uplift in operating expenses that will compress margins and extend the timeline to profitability. While management emphasized financial independence, the sheer scale of these investments—combined with ongoing costs for the sales force expansion and potential commercialization activities for volixibat—creates a scenario where profitability remains elusive for multiple years, even if revenue guidance is met. The market may be underestimating the duration and intensity of this investment phase, particularly given that the company is simultaneously advancing three late-stage pipeline assets (volixibat, berlivatig, zolergosertib) toward potential approval and launch, each requiring substantial pre-launch spending on manufacturing, medical affairs, and market access. This prolonged investment window increases execution risk and could lead to investor impatience if clinical or regulatory milestones slip, especially given the company’s history of operating losses and the high valuation implied by its current growth expectations.
The commercial opportunity for LIVMARLI’s EXPAND indication, while cited by management as representing about one-third of at least a $1 billion peak sales opportunity, remains unproven and contingent on positive results from the ongoing Phase 3 EXPAND study, which has not yet read out. Management’s characterization of this opportunity as a near-term catalyst may be overly optimistic, as the study is evaluating additional settings of cholestatic pruritus beyond PFIC and Alagille, including intrahepatic cholestasis of pregnancy (ICP), and there is no guarantee of regulatory approval or reimbursement support in these broader indications. The company has not disclosed specific timelines for EXPAND readout or NDA submission, and the reliance on this indication to drive significant long-term growth introduces uncertainty, especially if the data fail to demonstrate a clinically meaningful benefit or if payer resistance emerges in newer, less established patient populations. Furthermore, LIVMARLI’s current label carries important limitations, including a boxed warning for liver injury and restrictions in PFIC type 2 patients with severe BSEP defects, which could complicate expansion into broader cholestatic populations where underlying liver heterogeneity is higher. The market may be assigning excessive value to the EXPAND opportunity without sufficient visibility into the study’s progress or the commercial viability of launching into indications where Mirum lacks established physician relationships or real-world evidence.
The FOP market for zolergosertib is inherently constrained by the disease’s ultra-rare prevalence, with only approximately 300 identified patients in the U.S. and 900 globally, which imposes a hard ceiling on revenue potential regardless of pricing or penetration. Management’s peak sales guidance of $200 million plus globally implies an exceptionally high annual revenue per patient—exceeding $600,000 per patient per year in the U.S. alone if fully penetrated—which raises questions about pricing sustainability and payer receptiveness, particularly in a landscape where ultra-rare disease therapies face increasing scrutiny from insurers and pharmacy benefit managers over cost-effectiveness. While the company compared pricing to Niemann-Pick C products, those analogs may not fully capture the unique burden of FOP, where patients often require multidisciplinary care and face significant disability, potentially limiting willingness to pay at such elevated levels. Additionally, the NDA is limited to patients age 12 and over, excluding a meaningful portion of the FOP population diagnosed in early childhood, and while management noted ongoing cohorts for younger ages, there is no guarantee of label expansion or timely data readouts to support it. The reliance on Incyte to complete the primary role through approval, with Mirum assuming sponsorship only post-approval, introduces operational handoff risk, and the fact that Incyte retains any rare pediatric disease priority review voucher—should one be awarded—reduces Mirum’s potential upside from non-economic incentives. The market may be overlooking these structural constraints and overestimating the speed and depth of penetration in a niche, challenging-to-reach patient population where diagnosis remains difficult and treatment paradigms are entrenched.
Mirum’s growing dependence on external partnerships and licensing deals—exemplified by the zolergosertib agreement with Incyte and the historical in-licensing of assets like CHOLBAM and CTEXLI—creates vulnerability to counterparty actions and reduces control over key pipeline assets, particularly regarding regulatory strategy, timing, and economic terms. In the zolergosertib deal, Incyte retains the rare pediatric disease priority review voucher if awarded, controls the primary regulatory role through approval, and is eligible for sales-based milestones and royalties, which means Mirum’s upside is capped and its downstream success is tied to Incyte’s execution. While management expressed confidence in the asset based on full access to data and regulatory correspondence, the company does not own the underlying intellectual property or development program outright, limiting its ability to influence critical decisions. This pattern extends to other pipeline assets: volixibat and berlivatig are internally developed, but the company’s reliance on external innovation for key growth drivers like zolergosertib introduces strategic fragility. If Incyte prioritizes other programs or encounters delays in the PROGRESS study readout or FDA review, Mirum’s timeline for launch and revenue recognition could slip, directly impacting its 2026 revenue guidance and long-term valuation. The market may be assuming seamless execution of these partnerships without adequately weighing the risks of misaligned incentives, clinical setbacks at the partner level, or changes in partner strategy that could diminish Mirum’s expected benefits.

Geographical Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Geographical Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password